Erin Bastick, PharmD, RPh
FDA approves Bayer’s Bluetooth-enabled auto-injector for multiple sclerosis
FDA has approved a supplemental Biologics License Application (sBLA) for Bayer’s myBETAapp and BETACONNECT Navigator for multiple sclerosis (MS) patients
Evolving hepatitis C pipeline offers hope to patients
Evolving hepatitis C pipeline offers hope to patients
Cost burden prompts payers to consider appropriate utilization
FDA to drug maker: Pull opioid pain drug
Potential public health consquences prompts FDA to request removal of opioid pain medication.
FDA approves EpiPen rival
Adamis’ epinephrine injection promises to be a lower-cost alterative to EpiPen.
FDA approves first generic Truvada for HIV
The first generic Truvada for treating and preventing HIV will be available, but when?
FDA gives once-daily HIV therapy go-ahead
FDA approves Isentress at a higher dose for HIV-1 infected patients.
Asthma biologic may reduce oral steroid use
A new trial for AstraZeneca’s benralizumab shows promising results for severe asthma patients.
First generic Strattera for ADHD approved
FDA has approved the first generic versions of Strattera (atomoxetine) for the treatment of attention deficit/hyperactivity disorder.
Pharmaceutical pipeline: Top 4 conditions to watch
Pharmaceutical pipeline: Top 4 conditions to watch
Although drug spend is increasing for inflammatory conditions, diabetes, and oncology, there are some promising developments in the pipeline.
Drugmaker recalls samples of antiplatelet drug
AstraZeneca voluntarily recalls professional samples of its antiplatelet agent. Here's what to do.

Poll

View Results